{"id":2232,"date":"2017-02-12T16:24:00","date_gmt":"2017-02-12T16:24:00","guid":{"rendered":"https:\/\/curateq.in-testing.co.uk\/?p=2232"},"modified":"2023-11-22T08:18:20","modified_gmt":"2023-11-22T08:18:20","slug":"aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag","status":"publish","type":"post","link":"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/","title":{"rendered":"Aurobindo Pharma forays into biosimilars development"},"content":{"rendered":"\n
\n
\n

Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG.<\/h3>\n

As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo and\/or its affiliates will develop, commercialise and market these products globally. The branded market size of these four biosimilars, three of them monoclonal antibodies in oncology is very promising. Regulatory filing for these products is intended in the period 2020-22.<\/p>\n

Aurobindo is preparing to take its lead molecule from this transaction, a Bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab is an anti-antiogenesis drug used in treating multiple-cancers including metastatic colon or rectal cancer, non-squamous and non-small cell lung cancers.<\/p>\n

This transaction is a strategic investment for future growth and will position Aurobindo as a strong player in the rapidly evolving biosimilars landscape. Building on these first four products licensed from TL, Aurobindo is expanding its diverse portfolio of eight more next wave of biosimilars ensuring a strong and diverse products pipeline. Aurobindo has set up a fully functional R&D centre for biologics development and is also establishing a state-of-art manufacturing facility in Hyderabad, Telangana which would be ready by Q2, FY 18<\/p>\n

Commenting on the strategic alliance, Mr. N. Govindarajan, Managing Director of Aurobindo Pharma Limited said: \u201cWe are impressed with TL\u2019s product development as these are developed to the highest standards of biosimilarity. This acquisition is in-line with our strategy of investing in complex products and is an important first step towards establishing Aurobindo\u2019s global biosimilars portfolio.\u201d<\/p>\n

Article reposted from Biosimilar Development<\/strong><\/a><\/p>\n <\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar…<\/p>\n","protected":false},"author":1,"featured_media":2119,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[14,19,20,21,22,23],"class_list":["post-2232","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","tag-biosimilars","tag-aurobindo-pharma","tag-monoclonal-antibodies","tag-oncology","tag-biosimilar-development","tag-bevacizumab-biosimilar"],"yoast_head":"\nAurobindo Pharma forays into biosimilars development - CuraTeQ Biologics<\/title>\n<meta name=\"description\" content=\"Aurobindo Pharma Limited acquires four cell culture derived products for biosimilar development from TL Biopharmaceutical AG.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aurobindo Pharma forays into biosimilars development - CuraTeQ Biologics\" \/>\n<meta property=\"og:description\" content=\"Aurobindo Pharma Limited acquires four cell culture derived products for biosimilar development from TL Biopharmaceutical AG.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/\" \/>\n<meta property=\"og:site_name\" content=\"CuraTeQ Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-12T16:24:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-22T08:18:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/curateqbio.com\/wp-content\/uploads\/2023\/03\/contact-building-shot.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"899\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"curateq-admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/curateqbio.com\/#website\",\"url\":\"https:\/\/curateqbio.com\/\",\"name\":\"CuraTeQ Biologics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/curateqbio.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/#primaryimage\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/curateqbio.com\/wp-content\/uploads\/2023\/03\/contact-building-shot.jpg\",\"contentUrl\":\"https:\/\/curateqbio.com\/wp-content\/uploads\/2023\/03\/contact-building-shot.jpg\",\"width\":1920,\"height\":899},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/#webpage\",\"url\":\"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/\",\"name\":\"Aurobindo Pharma forays into biosimilars development - CuraTeQ Biologics\",\"isPartOf\":{\"@id\":\"https:\/\/curateqbio.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/#primaryimage\"},\"datePublished\":\"2017-02-12T16:24:00+00:00\",\"dateModified\":\"2023-11-22T08:18:20+00:00\",\"author\":{\"@id\":\"https:\/\/curateqbio.com\/#\/schema\/person\/ada896a037198d1a34fed5ca62571235\"},\"description\":\"Aurobindo Pharma Limited acquires four cell culture derived products for biosimilar development from TL Biopharmaceutical AG.\",\"breadcrumb\":{\"@id\":\"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/curateqbio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aurobindo Pharma forays into biosimilars development\"}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/curateqbio.com\/#\/schema\/person\/ada896a037198d1a34fed5ca62571235\",\"name\":\"curateq-admin\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/curateqbio.com\/#personlogo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1f5bfa143bdcee393defa3cc5e4dd1b8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1f5bfa143bdcee393defa3cc5e4dd1b8?s=96&d=mm&r=g\",\"caption\":\"curateq-admin\"},\"sameAs\":[\"http:\/\/curateq.local\"],\"url\":\"https:\/\/curateqbio.com\/author\/curateq-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aurobindo Pharma forays into biosimilars development - CuraTeQ Biologics","description":"Aurobindo Pharma Limited acquires four cell culture derived products for biosimilar development from TL Biopharmaceutical AG.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/","og_locale":"en_US","og_type":"article","og_title":"Aurobindo Pharma forays into biosimilars development - CuraTeQ Biologics","og_description":"Aurobindo Pharma Limited acquires four cell culture derived products for biosimilar development from TL Biopharmaceutical AG.","og_url":"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/","og_site_name":"CuraTeQ Biologics","article_published_time":"2017-02-12T16:24:00+00:00","article_modified_time":"2023-11-22T08:18:20+00:00","og_image":[{"width":1920,"height":899,"url":"https:\/\/curateqbio.com\/wp-content\/uploads\/2023\/03\/contact-building-shot.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Written by":"curateq-admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebSite","@id":"https:\/\/curateqbio.com\/#website","url":"https:\/\/curateqbio.com\/","name":"CuraTeQ Biologics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/curateqbio.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/#primaryimage","inLanguage":"en-US","url":"https:\/\/curateqbio.com\/wp-content\/uploads\/2023\/03\/contact-building-shot.jpg","contentUrl":"https:\/\/curateqbio.com\/wp-content\/uploads\/2023\/03\/contact-building-shot.jpg","width":1920,"height":899},{"@type":"WebPage","@id":"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/#webpage","url":"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/","name":"Aurobindo Pharma forays into biosimilars development - CuraTeQ Biologics","isPartOf":{"@id":"https:\/\/curateqbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/#primaryimage"},"datePublished":"2017-02-12T16:24:00+00:00","dateModified":"2023-11-22T08:18:20+00:00","author":{"@id":"https:\/\/curateqbio.com\/#\/schema\/person\/ada896a037198d1a34fed5ca62571235"},"description":"Aurobindo Pharma Limited acquires four cell culture derived products for biosimilar development from TL Biopharmaceutical AG.","breadcrumb":{"@id":"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/curateqbio.com\/aurobindo-pharma-forays-into-biosimilars-development-through-an-acquisition-of-four-products-from-tl-biopharmaceutical-ag\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/curateqbio.com\/"},{"@type":"ListItem","position":2,"name":"Aurobindo Pharma forays into biosimilars development"}]},{"@type":"Person","@id":"https:\/\/curateqbio.com\/#\/schema\/person\/ada896a037198d1a34fed5ca62571235","name":"curateq-admin","image":{"@type":"ImageObject","@id":"https:\/\/curateqbio.com\/#personlogo","inLanguage":"en-US","url":"https:\/\/secure.gravatar.com\/avatar\/1f5bfa143bdcee393defa3cc5e4dd1b8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1f5bfa143bdcee393defa3cc5e4dd1b8?s=96&d=mm&r=g","caption":"curateq-admin"},"sameAs":["http:\/\/curateq.local"],"url":"https:\/\/curateqbio.com\/author\/curateq-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/posts\/2232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/comments?post=2232"}],"version-history":[{"count":14,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/posts\/2232\/revisions"}],"predecessor-version":[{"id":2440,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/posts\/2232\/revisions\/2440"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/media\/2119"}],"wp:attachment":[{"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/media?parent=2232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/categories?post=2232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/tags?post=2232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}